Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris

Comparison of the efficacy of LEO 90100 foam with Dovobet® ointment in the treatment of psoriasis in Japanese subjects.

Study Overview

• Status: Completed
• Conditions: Psoriasis Vulgaris
• Intervention / Treatment: Drug: LEO 90100 foam; Drug: Dovobet® ointment

Detailed Description

A phase 3, national, multi-centre, 4-week, prospective, randomised, controlled, parallel-group, open trial of LEO 90100 foam versus Dovobet® ointment (both treatments containing calcipotriol hydrate plus betamethasone dipropionate) in Japanese subjects with psoriasis vulgaris.

• Study Type: Interventional
• Enrollment (Actual): 182
• Phase: Phase 3

Contacts and Locations

Study Locations

• Japan
  • Fukuoka
    • Fukutsu, Fukuoka, Japan, 811-3217
      • LEO Pharma Investigational Site
  • Hokkaido
    • Obihiro, Hokkaido, Japan, 080-0013
      • LEO Pharma Investigational Site
    • Sapporo, Hokkaido, Japan, 004-0063
      • LEO Pharma Investigational Site
    • Sapporo, Hokkaido, Japan, 006-0814
      • LEO Pharma Investigational Site
    • Sapporo, Hokkaido, Japan, 060-0807
      • LEO Pharma Investigational Site
  • Ishikawa
    • Nonoichi, Ishikawa, Japan, 921-8801
      • LEO Pharma Investigational Site
  • Kanagawa
    • Kawasaki, Kanagawa, Japan, 213-0001
      • LEO Pharma Investigational Site
    • Yokohama, Kanagawa, Japan, 220-6208
      • LEO Pharma Investigational Site
  • Miyagi
    • Sendai, Miyagi, Japan, 981-3133
      • LEO Pharma Investigational Site
  • Saitama
    • Saitama-shi, Saitama, Japan, 330-0854
      • LEO Pharma Investigational Site
  • Tokyo
    • Itabashi-ku, Tokyo, Japan, 173-8605
      • LEO Pharma Investigational Site
    • Kita-ku, Tokyo, Japan, 115-0045
      • LEO Pharma Investigational Site
    • Koto-Ku, Tokyo, Japan, 136-0074
      • LEO Pharma Investigational Site
    • Minato-Ku, Tokyo, Japan, 108-0014
      • LEO Pharma Investigational Site
    • Setagaya, Tokyo, Japan, 158-0094
      • LEO Pharma Investigational Site
    • Setagaya, Tokyo, Japan, 158-0097
      • LEO Pharma Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Key Inclusion Criteria:

1. Signed and dated informed consent obtained
2. Japanese subjects
3. Aged 20 years or above
4. Clinical diagnosis of psoriasis vulgaris amenable to topical treatment of less than or equal to 30% BSA (excluding psoriasis on the face/genitals/skin folds).
5. A target psoriasis lesion of at least mild severity on the body of a minimum size of 10 cm2 and scoring at least 2 (mild) for each of the clinical signs). The lesion must not be on the scalp, face, genitals or skin folds.
6. Women of childbearing potential must have a negative pregnancy test at Day 1 and agree to use an adequate methods of birth control during the trial.
7. Able to communicate with the (sub)investigator and understand and comply with the requirements of the trial.

Key Exclusion Criteria:

1. Systemic use of biological treatments with a potential effect on psoriasis vulgaris within the specified time periods prior to randomisation (depending on treatment)
2. Systemic treatments with all therapies other than biological treatments with a potential effect on psoriasis vulgaris within 4 weeks prior to randomisation
3. PUVA therapy, UVB therapy or UVA therapy on the full body or on the target lesion within 4 weeks prior to randomisation
4. Topical treatment of psoriasis on the areas to be treated with trial medication within 2 weeks prior to randomisation
5. Topical treatment of psoriasis on the face, genitals or skin folds with vitamin D3 analogues, potent corticosteroids or immunosuppressants within 2 weeks prior to randomisation
6. Topical treatment of conditions other than psoriasis with vitamin D3 analogues, potent corticosteroids or immunosuppressants within 2 weeks prior to randomisation
7. Initiation or changes of medication that may affect psoriasis vulgaris during the trial
8. Patients with certain disorders or symptoms present on the areas to be treated with trial medication: viral lesions of the skin, infections, skin manifestations, or fragility of skin veins
9. Other inflammatory skin diseases that may confound the evaluation of psoriasis vulgaris
10. Erythrodermic, exfoliative or pustular psoriasis on the areas to be treated with trial medication
11. Planned excessive exposure of areas to be treated with trial medication to either natural or artificial sunlight during the trial.
12. Disorders of calcium metabolism
13. Severe renal insufficiency, severe hepatic disorders or severe heart disease
14. Hypersensitivity to any components of the investigational medicinal products.
15. Cushing's disease or Addison's disease
16. Subjects who have received treatment with any non-marketed drug substance within the 4 weeks prior to randomisation, or longer if for certain biological treatments
17. History of cancer within the last 5 years (except completely cured skin cancer)
18. Current participation in any other interventional clinical trial
19. Previously randomised in this trial
20. Women who are pregnant, wishing to become pregnant or are breast-feeding
21. Chronic alcohol or drug abuse within 12 months prior to screening, or any condition associated with poor compliance
22. Employees of the trial site or any other individuals directly involved with the planning or conduct of the trial, or immediate family members of such individuals

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: LEO 90100 foam; calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g	Drug: LEO 90100 foam; Once daily topical application of foam from a can to psoriasis lesions. Dose depends on size of lesion.; Other Names: Enstilar® Foam
Active Comparator: Dovobet® ointment; calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g	Drug: Dovobet® ointment; Once daily topical application of ointment from a tube to psoriasis lesions. Dose depends on size of lesion.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Improvement Rate for the Target Lesion	Overall improvement defined as 'Substantial Resolution' of Clinical Signs or at Least 'Moderately Improved' in the General Change in the Lesion. Substantial resolution' is defined as a clinical score for thickness and scaliness of 0 and a clinical score for redness of 1 or less in the severity of clinical signs of the target lesion. The details of the clinical scores are presented in secondary outcome measure description for 'Change in the total sign score'. Change in the Lesion is a 5 point scale below: Markedly improved (best outcome); Moderately improved; Slightly improved; Unchanged; Aggravated (worst outcome)	End of Week 4

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Improvement Rate for the Target Lesion at Weeks 1 and 2	Substantial resolution of clinical signs or at least 'moderately improved' in the general change in the target lesion. Change in the Lesion is a 5 point scale below: Markedly improved (best outcome); Moderately improved; Slightly improved; Unchanged; Aggravated (worst outcome)	End of Weeks 1 and 2
Change in the Total Sign Score for the Target Lesion From Week 0 to Week 4	The change in the total sign score from Week 0 to Week 4; total sign score is defined as the sum of the scores from the 3 clinical signs (redness, thickness, and scaliness) assessing severity in the target lesion. The severity for each of the 3 clinical signs was recorded according to a 9-point scale that ranges from a score of 0 to 4 in increments of 0.5; the severities are scored from low to high with 0 = none and 4 = severe. The sum of the 3 total sign scores could range from 0 (best) to 12 (worse). The greater the negative value for the change means a better outcome. Negative change denotes a decrease in the score and therefore a decrease in disease severity.	End of Week 4
Number of Adverse Events	Number of treatment emergent adverse events (TEAEs). 14-day follow-up of TEAEs was only required if the TEAE was present at the last visit, and was of possible or probable relationship to trial medication.	Treatment Emergent Adverse Events were assessed from Day 1 to end of Week 4, if Treatment Emergent Adverse Events were noted, they were followed for an additional 14 days

Collaborators and Investigators

• Sponsor: LEO Pharma

Study record dates

Study Major Dates

• Study Start (Actual): January 24, 2019
• Primary Completion (Actual): June 10, 2019
• Study Completion (Actual): June 10, 2019

Study Registration Dates

• First Submitted: January 15, 2019
• First Submitted That Met QC Criteria: January 15, 2019
• First Posted (Actual): January 16, 2019

Study Record Updates

• Last Update Posted (Actual): December 16, 2020
• Last Update Submitted That Met QC Criteria: November 20, 2020
• Last Verified: November 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Skin Diseases, Papulosquamous; Psoriasis
• Other Study ID Numbers: LP0053-1422

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Yes
• IPD Plan Description: De-identified Individual Participant Data can be made available to researchers in a closed environment for a specified period of time.
• IPD Sharing Time Frame: Data are available to request after results of the trial are available on leopharmatrials.com
• IPD Sharing Access Criteria: Data-sharing is subject to approved scientifically sound research proposal and signed data-sharing agreement.
• IPD Sharing Supporting Information Type: Study Protocol; Statistical Analysis Plan (SAP); Clinical Study Report (CSR)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No